UBE3A and cancer: This provides a rationale for a combination treatment of cancer cells with agents to stabilize PML such as emodin, XMD8-92, or anti-E6AP N-methyl peptide combined with DNA damaging agents and pro-senescence cytokines (Acosta and Gil, 2012).